Lahore: CITI PHARMA LTD has achieved a significant milestone by becoming Pakistan's foremost exporter of nutraceutical products and multivitamins to the United States. This announcement follows the formal approval and launch of the company's range in the US market as of September 2024.

CITI PHARMA, renowned as Pakistan's largest active pharmaceutical ingredient (API) manufacturer, has received the necessary FDA approvals for its diverse product line which includes treatments for fertility, weight management, stress and mood enhancement, hair and skin care, and joint and muscle pains. According to information available from the Pakistan Stock Exchange (PSX), this approval marks a pivotal step for CITI PHARMA, adhering to stringent international standards and securing entry into the competitive US health supplement arena.

The Lahore-based company boasts a comprehensive array of pharmaceutical and nutraceutical products, including tablets, capsules, powder sachets, syrups, ointments, gels, injections, and infusions. Under the leadership of CEO Mr. Rizwan, whose vision for high standards and product quality has propelled CITI PHARMA to the forefront of the industry, the company is set to expand its footprint globally.

Financially, CITI PHARMA anticipates generating revenue of approximately $3.00 million annually from this new venture, with profit margins expected between 25% and 30%. The successful FDA approval not only enhances the company's credibility but also positions it for further international growth and potential partnerships.

Moreover, CITI PHARMA has confirmed receiving a payment of $109,500 for its first shipment to the US, cementing its status as a major player in the global pharmaceutical market.